Injectable Compounds To Treat Tmj Pain And Degerative Joint Disease

Songsong Zhu,Jing Hu

2013-01-01

Abstract:Osteoarthritis (OA) of the temporomandibular joint (TMJ) is characterized by progressive articular cartilage degradation and fibrillation in the cartilage, chondrocyte proliferation, concomitant adaptive or reparative osteogenesis or osteophyte formation at the joint margins, and sclerosis of the subchondral bone, all associated with inflammatory events that exacerbate joint tissue catabolism.(1,2) These degenerative lesions in cartilage and the subchondral bone lead to pain and dysfunction that dramatically affect patients' quality of life. Unfortunately, articular cartilage has a limited capacity for self-repair. Left untreated, defects in the cartilage layer often do not heal at all. Therefore, therapeutic intervention is required to improve the quality of the regeneration in the articular cartilage.Treatment of OA includes rest of the jaw, the use of pharmaceuticals, bite appliance therapy, thermotherapy, and minimally invasive surgical treatments.(3-5) Open surgery and the replacement of the TMJ are methods that are only used when all other possible therapeutic options have been exhausted.(2,6) Because of the ease of application and relatively small degree of invasion, intra-articular therapies have become a standard part of the treatment of TMJ-OA. However, the various drugs injected into joints can cause different effects on the degenerative lesions. Only if an adequate and correct injectable drug is selected will the therapeutic effects be successful.Under normal conditions, the metabolism of mature articular cartilage is maintained by the balance between catabolic and anabolic factors that originate from cellular production within the cartilage as well as from the synovial fluid and surrounding tissues. During the progress of TMJ-OA, endogenous growth factors are generally associated with the regulation of acute and chronic inflammation and connective tissue destruction (see chapters 3 and 14). The generation of these factors in TMJ diseases and their ability to induce the secretion of other potent biologic mediators may be part of the cascade of events that leads to the cartilaginous and bony degradation. As the mechanisms of action for these factors are established through well-defined in vitro and in vivo studies, it is becoming clear that they may eventually serve to augment current cartilage repair techniques. Thus, it is essential in the repair of articular cartilage to suppress overexpression of catabolic factors and stimulate secretion of anabolic factors. The following sections provide an overview of the developments regarding the intra-articular injection of these factors for the management of degenerative lesions in the TMJ as well as a discussion of the future potentials of this treatment method.